Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

This article was originally published on Nasdaq

Shares of Sarepta Therapeutics SRPT plunged almost 20% on Mar 16, soon after the company announced the FDA’s decision to hold an unexpected advisory meeting for the biologics license application (BLA) of its lead gene therapy candidate SRP-9001.